4 days Sanofi’s Sarclisa Gets FDA Nod for Expanded Use in Multiple Myeloma Zacks
This latest FDA decision marks the first approval for SNY’s Sarclisa as a first-line treatment for multiple myeloma patients.
This latest FDA decision marks the first approval for SNY’s Sarclisa as a first-line treatment for multiple myeloma patients.